Barrow, Hanley, Mewhinney & Strauss’s GSK GSK Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-143,538	Closed	-$6.86M	–	352
2018 Q4	$6.86M	Hold	143,538	–	–	0.01%	152
2018 Q3	$7.21M	Sell	143,538 -44,622	-24%	-$2.27M	0.01%	163
2018 Q2	$9.48M	Hold	188,160	–	–	0.02%	159
2018 Q1	$9.19M	Hold	188,160	–	–	0.01%	155
2017 Q4	$8.34M	Hold	188,160	–	–	0.01%	159
2017 Q3	$9.55M	Hold	188,160	–	–	0.01%	158
2017 Q2	$10.1M	Hold	188,160	–	–	0.02%	158
2017 Q1	$9.92M	Hold	188,160	–	–	0.01%	157
2016 Q4	$9.06M	Hold	188,160	–	–	0.01%	159
2016 Q3	$10.1M	Sell	188,160 -13,280	-7%	-$728K	0.02%	157
2016 Q2	$10.9M	Hold	201,440	–	–	0.02%	156
2016 Q1	$10.2M	Buy	201,440 +2,240	+1%	+$112K	0.02%	148
2015 Q4	$10M	Hold	199,200	–	–	0.02%	150
2015 Q3	$9.57M	Sell	199,200 -2,640	-1%	-$137K	0.01%	149
2015 Q2	$10.5M	Sell	201,840 -14,880	-7%	-$838K	0.01%	151
2015 Q1	$12.5M	Hold	216,720	–	–	0.02%	156
2014 Q4	$11.6M	Hold	216,720	–	–	0.02%	155
2014 Q3	$12.5M	Hold	216,720	–	–	0.02%	158
2014 Q2	$14.5M	Buy	+216,720	New	+$14.7M	0.02%	160

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's GSK Position: Q1 2019 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of GSK (GSK) in Q1 2019, closing a stake of 143,538 shares — an estimated $6.86M sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in GSK in Q2 2014 and held it in 19 quarters. The position peaked at $14.5M in Q2 2014. 847 funds tracked by Wall St. Rank hold GSK as of Q1 2019.

Barrow, Hanley, Mewhinney & Strauss reported no remaining GSK position as of Q1 2019 after selling out during the quarter.
Barrow, Hanley, Mewhinney & Strauss sold 143,538 GSK shares in Q1 2019, an estimated $6.86M.
Barrow, Hanley, Mewhinney & Strauss first reported a position in GSK in Q2 2014 and held it in 19 quarters.
Barrow, Hanley, Mewhinney & Strauss's GSK position peaked at $14.5M in Q2 2014.
847 funds tracked by Wall St. Rank held GSK as of Q1 2019.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q1 2019, filed 14 May 2019.